Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191684 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
A Phase 1 study of Stage III Pancreatic Cancer and Recurrent Colon Cancer, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01191684: Completed Phase 1 study of Stage III Pancreatic Cancer and Recurrent Colon Cancer, sponsored by City of Hope Medical Center.
NCT01191684 is a Phase 1 study of Stage III Pancreatic Cancer and Recurrent Colon Cancer that has completed, run by City of Hope Medical Center. The registered enrollment target is 12 participants, below the 166-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01191684, a Phase 1 study of Stage III Pancreatic Cancer and Recurrent Colon Cancer, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with colorectal, stomach, or pancreatic cancer.
Primary Outcome
Safety data for each administered dose will be summarized using descriptive numbers and 95% confidence intervals from the exact binomial distributions
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER flow cytometry
- OTHER immunoenzyme technique
- OTHER enzyme-linked immunosorbent assay
- BIOLOGICAL modified vaccinia virus ankara vaccine expressing p53
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
What the finished NCT01191684 record still lists
NCT01191684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 166-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (93% lower).
The record links to 10 conditions, with Stage III Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01191684 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01191684 about?
NCT01191684 is a clinical study titled "Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer". RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with colorectal, stomach, or pancreatic cancer.
What is the current status of trial NCT01191684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-10. Estimated completion is 2013-08.
What conditions does trial NCT01191684 study?
This clinical trial studies the following conditions: Stage III Pancreatic Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Recurrent Pancreatic Cancer, Stage III Colon Cancer.
What interventions are being tested in trial NCT01191684?
The interventions under investigation include: laboratory biomarker analysis (OTHER), flow cytometry (OTHER), immunoenzyme technique (OTHER), enzyme-linked immunosorbent assay (OTHER), modified vaccinia virus ankara vaccine expressing p53 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01191684?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01191684 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01191684's enrollment target sits among peer trials
12 13th of 13 higher than 1 of 13 other Stage III Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
COMPLETED · Phase 1
-
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
COMPLETED · Phase 1
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia